Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:depression
|
| gptkbp:administered_by |
injection
oral tablet |
| gptkbp:approves |
gptkb:2006
gptkb:FDA |
| gptkbp:available_in |
tablet form
injection form |
| gptkbp:available_on |
generic medication
|
| gptkbp:brand |
gptkb:Invega_Sustenna
gptkb:Invega_Trinza |
| gptkbp:casnumber |
144598-75-4
|
| gptkbp:chemical_formula |
C23 H27 Cl N4 O3 S
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
first-line treatment for schizophrenia
maintenance treatment for schizophrenia |
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to paliperidone |
| gptkbp:developed_by |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:dosage_form |
extended-release tablet
sustained-release injection |
| gptkbp:duration |
long-term
|
| gptkbp:formulation |
intramuscular injection
oral solution |
| https://www.w3.org/2000/01/rdf-schema#label |
paliperidone
|
| gptkbp:interacts_with |
CYP3 A4 inducers
CYP2 D6 inhibitors |
| gptkbp:is_monitored_by |
gptkb:weight
lipid profile blood glucose |
| gptkbp:lifespan |
23 hours
|
| gptkbp:marketed_as |
gptkb:Invega
|
| gptkbp:mechanism_of_action |
dopamine D2 receptor antagonist
serotonin 5-HT2 A receptor antagonist |
| gptkbp:patient_population |
gptkb:children
adults |
| gptkbp:pharmacokinetics |
highly protein-bound
metabolized by liver sedative effects antipsychotic effects |
| gptkbp:related_to |
gptkb:risperidone
|
| gptkbp:requires |
not recommended in pregnancy
caution in elderly patients requires monitoring for metabolic changes |
| gptkbp:rounds |
urine
|
| gptkbp:side_effect |
metabolic syndrome
drowsiness cardiovascular events weight gain extrapyramidal symptoms neuroleptic malignant syndrome tardive dyskinesia hyperprolactinemia |
| gptkbp:used_for |
schizophrenia
schizoaffective disorder |
| gptkbp:bfsParent |
gptkb:CYP1_A2
gptkb:Invega_Sustenna gptkb:Invega_Trinza gptkb:Invega |
| gptkbp:bfsLayer |
7
|